1Chan JL, Abrahamson MJ. Pharmacological management of type
2diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc2003 ;78: 459 - 467.2.De Witt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA 2003;289: 2265 - 2269.
3De Witt DE, Hirsch IB. Outpatient insulin therapy in type 1 andtype 2 diabetes mellitus: scientific review. JAMA 2003, 289: 2254 -2264.
4Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation2004; 109:1497 - 1502.
5Schiffrin A. Nighttime continuous subcutaneous insulin infusion revisited: a strategy for improving inulin delivery. Diabetes Care2000;23:571 - 573.
6Purrello F, Rabuazza AM. Metabolic factors that affect beta -cell function and survival. Diabet Nutr metab 2000; 13: 84 - 91.
720. Sivitz WI. Lipotoxicity and glucotoxicity in type 2 diabetes.Postagrad Med 2001; 109: 55 - 59.
8Zhang CY, Baffy G, Perret P, et al. Uncoupling protein 2 negatively regulates insulin secretion and is a major link between obesity, βcell dysfunction, and type 2 diabetes. Cell 2001; 105:745 - 755.
9Rachman J, Payne MJ, Levy JC, et al. Changes in Amylin and Amylin- Like Peptide Concentrations and beta - Cell Function in Response to Sulfonylurea or Insulin Therapy in NIDDM. Diabetes Care 1998;21(5) :810 - 816.
10Ilkova H, Glaser B, Tunckale A, et al. Induction of long - term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin teeatment. Diabetes Care 1997; 20:1353 -1356.
